Table 2.
Demographics, clinical activity measures and IP-10 analysis of localized scleroderma (LS) patients and controls (psoriasis and healthy) participating in tissue analysis
| Clinical and laboratory features of tissue analyses subjects |
LS subjects |
Healthy controls |
Psoriasis controls |
|---|---|---|---|
| (number = 5) | (number = 2) | (number = 2) | |
| Demographic information |
Number (%) |
Number (%) |
Number (%) |
| Female |
4 (80) |
1 (50) |
2 (100) |
| Ethnicity: |
|
|
|
| Caucasian |
5 (100) |
1 (50) |
2 (100) |
| African American |
--- |
1 (50) |
--- |
| Subtype: |
|
|
|
| Linear (trunk/limb) |
3 (60) |
--- |
--- |
| Plaque (circumscribed superficial) |
2 (40) |
--- |
--- |
| Age |
Median (IQR) |
Ages in years |
Ages in years |
| Age at onset, years |
13 (6 to 16) |
--- |
--- |
| Age at biopsy, years |
13 (10 to 16) |
17, 18 |
34, 47 |
| Tissue analysis |
Number (%) |
Number (%) |
Number (%) |
| IP-10 staining present in cellular infiltrate |
5 (100) |
0 (0) |
2 (100) |
| Degree of cellular infiltratea |
|
|
|
| Mild (1 to 50) |
3 (60) |
2 (100) |
0 (0) |
| Moderate (51 to 150) |
2 (40) |
0 (0) |
2 (100) |
| Clinical measures and plasma IP-10 of LS patientsb |
Median (IQR) |
|
|
| PGA-A |
48 (41 to 52) |
--- |
--- |
| mLoSSI |
7 (7 to 8) |
--- |
--- |
| Plasma level of IP-10 (pg/ml)c | 2,814 (745 to 3,081) | --- | --- |
aAverage cellular infiltrate in skin: out of three high power fields: 1 to 50 = mild; 51 to 150 = moderate; >150 severe; bclinical and plasma measures obtained at first pediatric rheumatology visit, which was within 12 weeks of the biopsy date; cdetermined by Luminex assay. IP-10, interferon-gamma inducible protein-10; IQR, interquartile range; mLoSSI, modified Localized Scleroderma Skin Score; PGA-A, physicians global assessment of activity.